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Abstract
Background: Patients with hemophilia B are increasingly treated with extended half-
life (EHL) factor IX (FIX) concentrates. For the laboratory, introduction of these EHL 
concentrates presents a major challenge. To understand the variation in FIX activity 
levels, all available diagnostic assays need to be directly compared.
Methods: The ECAT, UKNEQAS, and RCPAQAP have collaboratively performed a 
global survey to evaluate the quality of FIX measurements using FIX deficient plasma 
samples spiked with recombinant FIX (rFIX), rFIXFP, rFIXFc, and N9-GP to levels at 
typical FIX trough (6 IU/dL) and peak levels (60 IU/dL). Participants were asked to use 
their routine protocols, using one-stage assays (OSA) or chromogenic assays (CA).
Results: In samples spiked with 6 IU/dL product, median (25%-75% range) FIX ac-
tivity levels (OSA), were 8.0 IU/dL (7.0-9.2) for rFIX, 6.0 IU/dL (4.0-7.1) for rFIXFP, 
6.6 IU/dL (5.5-8.0) for rFIXFc, and 4.9 IU/dL (3.5-8.4) for N9-GP. In samples spiked 
with 60 IU/dL, FIX activity levels measured (using OSA) was 63.0 IU/dL (59.9-67.0) 
for rFIX, 42.5 IU/dL (28.2-47.0) for rFIXFP, 50.0 IU/dL (45.0-55.0) for rFIXFc, and 
34.0 IU/dL (24.8-67.5) for N9-GP. Considerable differences were observed between 
reagents for all samples. With CA, there was also quite some variation, but no differ-
ences between reagents.
Conclusion: Large variation is observed in the measurement of FIX activity levels 
after administration of rFIX and EHL FIX products. For N9-GP, most silica-based as-
says show especially high levels. It is essential to standardize and improve reliability 
of measurements of these concentrates as diagnosis and treatment monitoring is 
based on these results.
K E Y W O R D S
extended half-life products, external quality control, factor IX, hemophilia B, laboratory 
diagnosis
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1  | INTRODUC TION
Patients with hemophilia B, an X-linked recessive bleeding disorder 
caused by deficiency of coagulation factor IX (FIX), have a high risk 
of (spontaneous) bleeding. These patients are treated prophylactically 
or on demand in case of bleeding with replacement therapy eg, FIX 
concentrates. Traditionally, the FIX concentrates were purified from 
human plasma. Since 1997 recombinant FIX (rFIX) is used to treat pa-
tients, minimizing risks of infections with blood-transferred diseases.1 
The latest recent therapeutic innovations include development of 
extended half-life (EHL) concentrates.2-4 Different technologies have 
been used to prolong FIX half-life: for rFIXFP (Idelvion®) FIX albumin 
fusion was performed, for rFIXFc (Alprolix®) FIX-Fc fragment IgG1 fu-
sion, and for N9-GP (Refixia®/Rebinyn®) on glycopolyethylene glycol 
(PEG)ylation (active component: nonacog beta pegol) was applied.5 
The introduction of EHL concentrates may improve quality of life by 
reducing injection frequency from several times weekly with standard 
half-life (SHL) concentrates to once weekly.5,6
For the laboratory, introduction of FIX EHL concentrates presents 
a major challenge, as these concentrates often behave differently in 
the assays that determine FIX levels than the traditional SHL products. 
At the moment, the available FIX assays are based on two principles. 
The first, and most-used type of diagnostic assay for FIX levels, is the 
one-stage clotting activity (OSA) measurement, an activated partial 
thromboplastin time (aPTT)-based assay. These assays mainly use 
either ellagic acid, silica, or kaolin as activators, and these activators 
give similar results when we use them to measure FIX levels in a diag-
nostic setting in most cases However, different results have also been 
reported for some of these OSA assays.7-16 Also, in external quality 
assessment programs, such as external quality control of diagnostic 
assays and tests (ECAT), UKNEQAS (blood coagulation), and the Royal 
College of Pathologists of Australasia Quality Assurance Program 
(RCPAQAP) in which plasma FIX is analyzed in diagnostic surveys, no 
large differences have been demonstrated between activators, aPTT 
reagents, deficient plasmas, and applied instruments. The alternative 
method is the chromogenic two-stage method (CA), with a first stage 
in which the generation of activated factor X (FXa) depends on the 
activity of the plasma FIX, and a second stage in which color is gener-
ated by FXa from a chromogenic substrate. The guideline on the dec-
laration of the quantitative composition/potency labeling of biological 
medicinal products that contain modified proteins as active substance 
published by the European Medicine Agency (EMA) and effective from 
September 2014 indicates that potency assays for each modified coag-
ulation factor concentrate should be based on in vitro and in vivo clin-
ical studies of assay methods involving multiple methods and reagents 
and that labeling can be in international units (IU) based on statistical 
validity when assayed against the relevant International standard.17 
This is also recommended by Scientific and Standardisation Committee 
(SSC) of the International Society on Thrombosis and Haemostasis 
(ISTH) on potency labelling of factor VIII and factor IX concentrates.18 
Several studies have shown that the different EHL FIX concentrates 
show different results with the different assays, which may result in 
both under- or overestimation of FIX. This is seen for OSA assays with 
different activators but also between OSA and CA.16,19-26 A workshop 
involving the European Medicine Association (EMA) and manufactur-
ers underlined concerns with regard to assay discrepancies in modified 
SHL and EHL concentrates and provided both information and advice 
to manufacturers and clinical laboratories regarding how to approach 
potency labeling and to perform reliable clinical monitoring.27
However, a comprehensive field study in which a wide variety of 
available diagnostic assays are directly compared has not yet been 
performed. Such a study is essential in understanding the variation 
in measured FIX activity level in patients using EHL concentrates and 
to manage differences between laboratories as this will affect the 
introduction and safety of clinical protocols. Furthermore, it is es-
sential to establish analytical performance of the various FIX assays 
for FIX EHL concentrates currently available.
To obtain a comprehensive overview of the analytical variation 
of the measurement of the plasma FIX activity using a wide range of 
commercially available FIX OSA and CA assays, we performed a global 
study in which the ECAT Foundation, UKNEQAS BC, and RCPAQAP 
collaborated in determining the analytical quality of FIX activity mea-
surements in plasma samples spiked with rFIXFP, rFIXFc, and N9-GP 
to levels that represent FIX trough (6 IU/dL) and peak (60 IU/dL) levels. 
Participants in the external quality control programs were asked to use 
their routine protocols. This study will gain insight into the underlying 
laboratory methods that may explain discrepancies.
2  | MATERIAL S AND METHODS
2.1 | Study design
Invitations to participate in this study were sent to all FIX participants 
of the external quality control programs from the non-profit organi-
zations ECAT (n = 175), UKNEQAS (n = 91), and RCAPQAP (n = 18). 
Results from spiked FIX samples were received from hemostasis 
Essentials
• The introduction of extended half-life concentrates for 
factor IX (FIX) presents a major challenge for the diag-
nostic laboratory.
• External Quality Organisations (ECAT, UKNEQAS, and 
RCPAQAP) have performed a global survey to evalu-
ate the quality of FIX measurements using FIX deficient 
plasma samples spiked with recombinant FIX (rFIX) and 
extended half-life (EHL) concentrates for FIX.
• Large variation is observed in the measurement of FIX 
activity levels in samples spiked with rFIX and EHL FIX 
products, both with one-stage and chromogenic assays.
• There is a need to standardize and improve the measure-
ment of FIX concentrates, because diagnosis and treat-
ment monitoring is based on these results.
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laboratories in 27 countries worldwide (Argentina, Australia, Belgium, 
Canada, Croatia, Denmark, Finland, France, Greece, Hong Kong, 
Hungary, Ireland, Israel, Italy, Malta, Netherlands, New Zealand, 
Poland, Portugal, Spain, Serbia, South Africa, Sweden, Switzerland, 
Thailand, United Kingdom, and United States) from ECAT (n = 64),28,29 
UKNEQAS (n = 82), and RCAPQAP (n = 18). Participating laborato-
ries were asked to perform FIX activity assays on each of the spiked 
samples, using their usual reagents and instruments for measuring FIX 
activity when monitoring post FIX concentrate infusion. Laboratories 
were asked, if possible, to perform both OSA and CA on these sam-
ples. Participants filled in a questionnaire for detailed information on, 
eg, assay methodology, instruments, reagents, and calibrator used. 
Participants were included if they reported at least one result of a 
measurement (n = 172).
2.2 | Study samples
Factor IX (FIX) deficient plasma from a severe hemophilia B patient 
without detectable FIX (George King Biomedical Inc) was spiked 
with one of the FIX concentrates (rFIXFP, rFIXFc, N9-GP, and rFIX 
[Benefix]). The absence of FIX in the deficient plasma was confirmed 
prior to spiking (<1 IU/dL). Each concentrate was spiked in two dif-
ferent concentrations (6 and 60 IU/dL). The concentration of the FIX 
products used was the potency label as defined by the pharmaceuti-
cal company. Concentrates often carry a nominal potency such as 
500 or 1000 IU as well as a more accurate assayed potency. The 
assayed potency (rather than nominal) was used for calculations of 
dilution factor to construct the 60 IU/dL samples. The 6 IU/dL sam-
ples were constructed by a 1 in 10 dilution of the 60 IU/dL sample 
using the same FIX deficient plasma as diluent. Plasma samples were 
then aliquoted and lyophilized as previously described by UKNEQAS 
before distribution.30
2.3 | Laboratory methods
The participating laboratories used either an OSA or a CA and in 
some cases used both. A wide variety of reagents and instruments 
were used (commercial and homemade). For the OSA, the majority of 
participants used IL HemosIL Synthasil, Siemens Actin FS, Siemens 
Pathromtin SL, Stago Cephalin/Kaolin/CK Prest as aPTT reagents 
and Werfen/IL ACL, Siemens BCS/BCS‒XP/BCT, Stago STA, and 
Sysmex as instruments. For the CA, the Rossix kit and the Hyphen 
kit were similarly used among laboratories.
2.4 | Statistical analysis
Data are presented as median, range, and coefficient of variation of 
the values and the median of the recovery, based on the potency as-
signed to the sample. Some participants filled in information on their 
methods, but only those participants were included in the analyses 
who also submitted measured values. All reported data are used 
in the analyses. Statistical analysis was performed using IBM SPSS 
Statistics version 24.
3  | RESULTS
3.1 | Reagents and instruments
The OSA was performed by 93% of the laboratories (160/172) who 
submitted at least one result; 120 laboratories only performed the 
OSA, while 35 laboratories reported both the OSA and the CA. In total 
41 laboratories performed the CA of which 35 reported results for 
both assays and six laboratories only the results of the CA (Table 1).
For the CA, the two available commercial kits (Hyphen kit and 
the Rossix kit), were used by 21 and 19 participating laboratories, 
respectively. Furthermore, 1 participant used an in-house chromo-
genic assay (Table 1).
3.2 | One-stage clotting assay
In samples spiked with 6 IU/dL product, the median (25%-75% range) 
FIX activity values were 8.0 IU/dL (7.0-9.2; median recovery 133%) 
for rFIX, 6.0 IU/dL (4.0-7.1, 100%) for rFIXFP, 6.6 IU/dL (5.5-8.0, 
TA B L E  1   Reagents used by the participants in the survey
Assay type N
One-stage assays 160
Silica 102
IL HemosIL Synthasil 68
Siemens Pathromtin SL 12
Stago PTT (automate) 9
IL HemosIL APTT-SP 4
Tcoag TriniCLOT APTT S 4
Tcoag TriniCLOT APTT HS 4
Stago PTT-LA 1
Polyphenolic 44
Siemens Actin FS 32
Siemens Actin FSL 5
Stago Cephascreen 4
Sekusiu Coagpia APTT-N 1
IL HemosIL SynthAFax 1
Diagnostic Grifols APTT synth 1
Kaolin 14
Stago Cephalin/Kaolin/CK Prest 14
Chromogenic two-stage assays 41
Hyphen 21
Rossix 19
Home made 1
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110%) for rFIXFc, and 4.9 (3.5-8.4, 82%) IU/dL for N9-GP (see 
Figure 1A). At 6 IU/dL, the between-laboratory variation (CV, coef-
ficient of variation) was in the same range for rFIX (CV 25%), rFIXFP 
(CV 41%), and rFIXFc (CV 36%), and with N9-GP we saw very large 
between-laboratory variation of 169%.
In samples spiked with 60 IU/dL, the median (25%-75% range) 
FIX activity was 63.0 IU/dL (59.9-67.0, median recovery 105%) for 
rFIX, while all FIX-EHL concentrates were underestimated with the 
OSA with 42.5 IU/dL (28.2-47.0, 71%) for rFIXFP, 50.0 IU/dL (45.0-
55.0, 85%) for rFIXFc, and 34.0 IU/dL (24.8-67.5, 57%) for N9-GP 
(Figure 1B). For the samples spiked with 60 IU/dL, the between-lab-
oratory variation (CV) was 12% for rFIX, 30% for rFIXFP, and 19% for 
rFIXFc. Also with the high dose, N9-GP showed a large between-lab-
oratory variation (CV 179%; Figure 1B).
A wide variation of reagents and instruments were used for the 
OSA. The aPTT activating reagents used among laboratories were 
silica (102 laboratories, 64%), ellagic acid (40 laboratories, 25%), 
kaolin (14 laboratories, 9%), and polyphenols (4 laboratories, 3%; 
Table 1). aPTT reagents that were used by the participating labo-
ratories used different activators, namely silica (n = 102; Tcoag 
TriniCLOT APTT S, Tcoag TriniCLOT APTT HS, Stago PTT-LA, Stago 
PTT (automate), Siemens Pathromtin SL, IL HemosIL Synthasil, 
and IL HemosIL APTT-SP), ellagic acid (n = 40; Siemens Actin FSL, 
Siemens Actin FS, Sekusiu Coagpia APTT-N, IL HemosIL SynthAFax, 
and Diagnostic Grifols APTT synth), cephalin/kaolin (n = 14; Stago 
Cephalin/Kaolin/CK Prest), or cephalin/polyohenolic (n = 4; Stago 
Cephascreen; Table 1).
Large between-laboratory differences in reported levels were 
seen for all FIX concentrates and with all different aPTT reagents at 
6 IU/dL (Figure 2A-D and Tables 2 and S1 in supporting information) 
and at 60 IU/dL (Figure 3A-D and Tables 3 and S1).
Considerable differences were observed between reagents, 
both for the low-dose and the high-dose samples, without there 
being a clear pattern. The mean FIX activity levels measured for rFIX 
were rather similar for all aPTT reagents for the low-dose sample 
(Figure 2A), but for the high-dose sample more variation was ob-
served (Stago PTT Automate, Tcoag TriniClot APTT-S, Siemens 
Actin FSL, and Stago Cephscreen showed higher median values; 
Figure 3A). Also for the low-dose rFIXFP similar median values were 
found for all aPTT reagents, except for IL HemosIL Synthasil and 
Siemens Pathromtin SL, which demonstrated slightly higher median 
values (Figure 2B). For the high-dose sample an underestimation 
of rFIXFP was observed with all aPTT reagents, except with Stago 
Cephascreen (Figure 3B). For rFIXFc similar results were obtained 
with the low-dose sample for almost all aPTT reagents. Only Stago 
APTT Automate gave slightly lower and Siemens Actin FSL slightly 
higher median values (Figure 2C). For the high dose of rFIXFc an un-
derestimation was measured with most of the aPTT reagents, except 
for Siemens Acin FS, Siemens Actin FSL, and Stago Cephascreen 
(Figure 3C). For N9-GP, significant differences were shown between 
different aPTT reagents, with strong overestimation for all sili-
ca-based aPTT reagents, except IL (HemosIL Synthasil; Figures 2D 
and 3D).
There was very limited variation in the combination of aPTT re-
agents and instruments, with 93% using both from the same company 
and only single laboratories using specific divergent combinations. 
Therefore, it was impossible to study the individual contribution of 
reagents and instruments to the between-laboratory variation. Also, 
80% of the laboratories used the calibrator from the same company 
as reagents and instrument. Other combinations were usually single 
laboratories, and therefore it was not possible to study the unique 
contribution of the calibrator.
3.3 | Chromogenic assay
Reported FIX activities for each product as measured with the CA 
are presented in Figure 1. In samples spiked with 6 IU/dL product, 
the median (25%-75% range) FIX activity values were 4.2 IU/dL 
F I G U R E  1   Boxplots of reported factor IX (FIX) levels (mean 
and standard deviation) for below typical trough levels of 6 IU/dL 
(Panel A) and peak levels of 60 IU/dL (Panel B) with one-stage and 
chromogenic FIX assays
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(3.8-5.0; median recovery 70%), 7.0 IU/dL (6.0-7.9, 117%), 4.2 IU/dL 
(3.8-5.5, 70%), and 5.0 IU/dL(4.0-6.0, 83%) for rFIX, rFIXFP, rFIXFc, 
and N9-GP, respectively (Figure 1A).
In samples spiked with 60 IU/dL, the median (25%-75%) abso-
lute FIX activity values were 45 IU/dL (40.5-79.0; median recovery 
75%); 73.3 IU/dL (65.3-81.9, 122%); 45.0 IU/dL (40.8-54.0, 75%); and 
53.6 IU/dL (46.2-60.0, 89%) for rFIX, rFIXFP, rFIXFc, and N9-GP re-
spectively (Figure 1B).
Both for the 6 and 60 IU/dL sample the between-laboratory vari-
ation (%CV) was similar for rFIX, rFIXFP, rFIXFc, and N9-GP (6 IU/
dL: 25.4%, 21.8%, 26.5%, and 25.8%, respectively; 60 IU/dL: 17.6%, 
22.2%, 19.7%, and 22.8%).
Significant differences were observed between the Hyphen 
and Rossix method for rFIX at both levels, rFIXFc at high levels, and 
N9-NP at low levels; the other results were not significantly differ-
ent (Figures 2A-D and 3A-D).
One determinant of the measured levels may be the calibrator 
used. Different calibrators were used for both chromogenic assays 
(Table S2 in supporting information), and for the high-dose sam-
ple significant differences were observed in the reported values. 
For rFIXFP, the reported values were higher than expected, and 
higher than for the other products, where reported values were 
lower than expected (Table S3 in supporting information). Also, 
within a product, we saw differences. With the same product we 
F I G U R E  2   Reported factor IX (FIX) levels (all reported values, mean and standard deviation) for below typical trough levels (6 IU/dL) 
with one-stage assays and chromogenic assay FIX reagents. A, rFIX; B, rFIXFP; C, rFIXFc; D, N9-GP. The Y-axis is broken to improve the 
presentation when there is a wide variation in results
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found different levels depending on the calibrator that was used 
(Table S3).
4  | DISCUSSION
In this global study on the analytical quality of measuring FIX activity 
in plasma samples spiked with rFIXFP, rFIXFc, and N9-GP to levels 
that represent FIX trough (6 IU/dL) and peak (60 IU/dL) levels, our 
main observations were that the reported values show a large vari-
ation both between products but also between laboratories. In ad-
dition, significant differences were demonstrated between reagents 
used in the OSA, especially in measuring N9-GP.
An important characteristic of this study is that our results reflect 
the real-life situation in laboratories that measure FIX activity. The 
study includes many laboratories from all over the world, using the 
available range of diagnostic assays and instruments. Centers used 
the assay design that would be applied when monitoring patients. 
At the same time, we realize that we live in a constantly changing 
world and new and improved reagents and instruments are becom-
ing available all the time. This emphasizes the need for continuous 
post-marketing surveillance as performed through proficiency test-
ing programs.
Measurement of FIX levels in patients treated with EHL concen-
trates is frequently needed as tailoring of dosing of the patients is in-
creasingly based on the results, as applied in pharmacokinetic-guided 
dosing for example. Undertreatment of patients may result in bleeding 
complications and should therefore be avoided. Differences between 
assays, leading to different FIX activity recovery levels, will have im-
pact on dosing regimens. However, we should be aware data is scarce 
on associations between FIX activity levels and bleeding risk.
In our study, levels measured in the samples spiked with rFIX 
were also not showing optimal recoveries. The recovery was in-
creased in the 6 IU/dL sample with OSA and decreased with CA, 
 rFIX rFIXFP rFIXFc N9-GP
OSA 
Silica
Median (IU/dL) 8.3 6.2 7.0 5.4
CV (%) 21.7 29.0 30.7 140
Range (IU/dL) 4.0-13.3 2.0-11.3 2.0-15.7 2.7-144.5
Median recovery (%) 138 103 117 90
Polyphenolic activator
Median (IU/dL) 7.3 4.0 7.0 3.0
CV (%) 40.0 40.8 51.7 132
Range (IU/dL) 5.1-21.0 2.0-10.6 4.0-19.0 1.47-52.7
Median recovery (%) 122 66 117 50
Cephalin/kaolin
Median (IU/dL) 8.0 3.5 5.0 3.0
CV (%) 14.9 50.7 32.5 43.4
Range (IU/dL) 6.1-10.0 0.8-8.1 1.3-8.0 0.8-7.0
Median recovery (%) 133 58 83 50
Chromogenic assays
Hyphen
Median (IU/dL) 3.8 6.3 3.8 4.3
CV (%) 14.6 14.2 13.5 19.4
Range (IU/dL) 2.9-5.0 4.9-8.0 3.0-5.0 2.0-6.0
Median recovery (%) 63 105 63 72
Rossix
Median (IU/dL) 5.0 7.5 5.5 6.0
CV (%) 16.8 20.3 19.5 22.7
Range (IU/dL) 3.7-7.2 5.0-11.5 4.0-8.4 3.0-8.7
Median recovery (%) 83 125 92 100
In house
Level (IU/dL) 8.0 3.0 4.0 3.0
Recovery (%) 133 50 67 50
TA B L E  2   One-stage clotting and 
chromogenic assays: results by aPTT 
activator, levels set at 6 IU/dL
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while it was slightly increased in the 60 IU/dL sample with OSA 
and also decreased with the CA. Previously, Sommer et al have 
also shown increased recovery with rFIX by OSA.8 In this study, 
the mean CV of the OSA were 44% and 31% for the low and high 
values, respectively, and 30% and 19% when we did not consider 
the large variation in N9-GP samples. In proficiency testing surveys 
utilizing samples containing native FIX these percentages are usu-
ally lower (around 20%-25% and 10% for low and normal values 
in ECAT and UKNEQAS regular EQA surveys). This indicates that, 
except for certain specific reagent effects with some products, the 
between-laboratory variation of EHL products is similar to that for 
the measurement of FIX in patients.
Also in this study, the lowest CVs occurred for the standard half-
life product. This suggests that all tested modifications on FIX that 
prolong their half-life in the products studied have some effect on 
OSA. The most dramatic effect was seen for N9-GP, where either 
lower levels were measured or extremely high levels. This difference 
could not be explained solely by the use of the class of activator, 
although all but one reagent using silica as activator showed very 
high FIX levels. It should be noted that there could be different forms 
F I G U R E  3   Reported factor IX (FIX) levels (all reported values, mean and standard deviation) for high levels (60 IU/dL) with one-stage 
assays and chromogenic assay FIX reagents. A, rFIX; B, rFIXFP; C, rFIXFc; D, N9-GP. The Y-axis is broken to improve the presentation when 
there is a wide variation in results
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of silica in different reagents that affect such relationships. Rosen 
et al studied the behavior of N9-GP in the aPTT assay. They observed 
that N9-GP, in the presence of one form of silica, is prematurely con-
verted to activated FIX (FIXa) during the contact activation phase of 
the clotting assay by activated FXI (FXIa) and plasma kallikrein (PK). 
They conclude that this phenomenon leads to the overestimation of 
the FIX activity in the OS clotting assay. This effect was not seen for 
native FIX.20 Also, Tiefenbacher et al did not see this.21
For the chromogenic assays the recovery percentages were 
slightly lower with Hyphen reagents than with Rossix. Both re-
agents measured median recovery higher than 100% for rFIXFP and 
below 100% recovery for the other drugs.27 The assignment of po-
tency to FIX products in Europe and North America is done by the 
one-stage assay. This is prescribed for both standard and EHL prod-
ucts although the full reagent details, such as aPTT reagent, are not 
available in the literature for all products to the best of the authors’ 
knowledge. Also, Tiefenbacher et al did not see this.21 One expla-
nation may be that we prepared our samples differently. We used 
the assayed potency value on the individual vials that were used to 
prepare the spiked samples in our calculations.
Another determinant may be the calibrator that was used. In our 
study it was not possible to evaluate this, because almost all labora-
tories used calibrator, reagent, and instrument from the same com-
pany. For the chromogenic assay this relationship was less tight and 
we could evaluate the different results for the four most-used cali-
brators. With the calibrators that were used within the chromogenic 
 rFIX rFIXFP rFIXFc N9-GP
OSA
Silica
Median (IU/dL) 62.0 45.0 48.5 35.0
CV (%) 12.4 12.8 14.3 141.5
Range (IU/dL) 49.0-87.5 26.7-60.0 28.0-59.5 25.0-1060
Median recovery 
(%)
103 75 81 58
Polyphenolic
Median (IU/dL) 64.3 24.0 56.5 18.5
CV (%) 12.8 23.6 15.2 34.0
Range (IU/dL) 53.0-90.0 17.5-77.0 43.0-80.0 13.0-70.0
Median recovery 
(%)
107 40 94 31
Kaolin
Median (IU/dL) 66.5 23.5 36.0 24.0
CV (%) 10.3 47.9 22.9 34.0
Range (IU/dL) 59.0-87.0 21.0-62.6 27.0-55.3 20.0-52.0
Median recovery 
(%)
111 39 60 40
Chromogenic assays
Hyphen     
Median (IU/dL) 42.0 72.0 43.8 52.0
CV (%) 10.2 22.9 14.4 24.5
Range (IU/dL) 33.3-52.0 30.0-122.0 36.3-64.0 30.0-97.0
Median recovery 
(%)
70 120 73 87
Rossix
Median (IU/dL) 47.7 77.2 53.0 56.0
CV (%) 18.8 15.0 21.1 17.2
Range (IU/dL) 31.0-60.9 58-100.10 33.0-74.1 41.0-75.7
Median recovery 
(%)
80 129 88 93
In house
Level (IU/dL) 68.0 23.0 35.0 23.0
Recovery (%) 113 38 58 38
TA B L E  3   One-stage clotting assay: 
results by aPTT activator, levels set at 
60 IU/dL
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assays, we see that the mean values for the high samples are lower 
than expected, based on the assigned value, for rFIX, rFIXIc, and 
N9-GP, while with all calibrators rFIXFP was higher than expected 
(Table S3). Also, within products, significant differences were ob-
served, with the lowest levels for all of the products measured using 
the Precision Biologic Normal Reference plasma.
It should also be considered that in this study we used spiked 
samples. This has some limitations compared to samples from pa-
tients using the medication. It is our experience (unpublished results) 
that samples with the products we now studied appear to be com-
mutable. Furthermore, the potency assignment to product vials is 
based on OSA and is based on OSA using a specific aPTT reagent/
analyzer protocol which is unlikely to match all protocols used by the 
study participants. Further, differences in methods of potency as-
signment between drugs may add to the observed variability found 
in this study. However, this assigned potency is what the doctors 
work with when deciding on the treatment of the patients.
In conclusion, a large variation is observed in FIX activity mea-
surement of EHL FIX concentrates using both OSA and CA assays, 
with over- and underestimation of the measured levels, without a 
clear pattern. Special attention should be given to patients on N9-
GP, as most silica-based assays give very high levels. It is essential to 
standardize FIX activity level measurement of EHL concentrates and 
to employ and develop assays that accurately measure the plasma 
FIX activity in patients using these products.
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